Shire intends to use the acquisition to expand its involvement in the therapeutic ophthalmology market.
Along with SARcode Biosciences, Shire will acquire the company’s dry eye disease treatment, LIFITEGRAST.
Shire intends to launch LIFTEGRAST in the U.S. by 2016.
More Articles on Ophthalmology:
Austin Dell Laser Consultants Offers Laser Treatment Options
Johns Hopkins Offers Implantable Macular Degeneration Treatment
Hemera Biosciences Receives $3.8M for Development of Macular Degeneration Treatment
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
